A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy

There is a need for efficacious therapies for metastatic castration-resistant prostate cancer (mCRPC) after disease progression on docetaxel. The SRC tyrosine kinase and its related family members may be important drivers of prostate cancer and can be inhibited by dasatinib. mCRPC patients, after on...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anti-cancer drugs 2013-08, Vol.24 (7), p.743-753
Hauptverfasser:	Twardowski, Przemyslaw W, Beumer, Jan H, Chen, C.S, Kraft, Andrew S, Chatta, Gurkamal S, Mitsuhashi, Masato, Ye, Wei, Christner, Susan M, Lilly, Michael B
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Dasatinib Disease-Free Survival Humans Indexing in process Male Middle Aged Orchiectomy Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - drug therapy Prostatic Neoplasms - mortality Prostatic Neoplasms, Castration-Resistant - blood Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - mortality Protein Kinase Inhibitors - therapeutic use Pyrimidines - therapeutic use Testosterone - blood Thiazoles - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!